Control of hyperglycaemia in paediatric intensive care (CHiP): study protocol.


Macrae, D; Pappachan, J; Grieve, R; Parslow, R; Nadel, S; Schindler, M; Baines, P; Fortune, PM; Slavik, Z; Goldmann, A; Truesdale, A; Betts, H; Allen, E; Snowdon, C; Percy, D; Broadhead, M; Quick, T; Peters, M; Morris, K; Tasker, R; Elbourne, D; (2010) Control of hyperglycaemia in paediatric intensive care (CHiP): study protocol. BMC Pediatr, 10 (1). p. 5. ISSN 1471-2431 DOI: https://doi.org/10.1186/1471-2431-10-5

[img]
Preview
Text - Published Version
License:

Download (3MB) | Preview

Abstract

ABSTRACT: BACKGROUND: There is increasing evidence that tight blood glucose (BG) control improves outcomes in critically ill adults. Children show similar hyperglycaemic responses to surgery or critical illness. However it is not known whether tight control will benefit children given maturational differences and different disease spectrum. METHODS: The study is an randomised open trial with two parallel groups to assess whether, for children undergoing intensive care in the UK aged <16 years who are ventilated, have an arterial line in-situ and are receiving vasoactive support following injury, major surgery or in association with critical illness in whom it is anticipated such treatment will be required to continue for at least 12 hours, tight control will increase the numbers of days alive and free of mechanical ventilation at 30 days, and lead to improvement in a range of complications associated with intensive care treatment and be cost effective. Children in the tight control group will receive insulin by intravenous infusion titrated to maintain BG between 4 and 7.0 mmol/l. Children in the control group will be treated according to a standard current approach to BG management. Children will be followed up to determine vital status and healthcare resources usage between discharge and 12 months post-randomisation. Information regarding overall health status, global neurological outcome, attention and behavioural status will be sought from a subgroup with traumatic brain injury (TBI). A difference of 2 days in the number of ventilator-free days within the first 30 days post-randomisation is considered clinically important. Conservatively assuming a standard deviation of a week across both trial arms, a type I error of 1% (2-sided test), and allowing for non-compliance, a total sample size of 1000 patients would have 90% power to detect this difference. To detect effect differences between cardiac and non-cardiac patients, a target sample size of 1500 is required. An economic evaluation will assess whether the costs of achieving tight BG control are justified by subsequent reductions in hospitalisation costs. DISCUSSION: The relevance of tight glycaemic control in this population needs to be assessed formally before being accepted into standard practice. Trial Registration Current Controlled Trials ISRCTN 61735247.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Medical Statistics
Faculty of Public Health and Policy > Dept of Health Services Research and Policy
Research Centre: Centre for Maternal, Reproductive and Child Health (MARCH)
Centre for Global Non-Communicable Diseases (NCDs)
PubMed ID: 20137090
Web of Science ID: 275399800001
URI: http://researchonline.lshtm.ac.uk/id/eprint/4113

Statistics


Download activity - last 12 months
Downloads since deposit
525Downloads
368Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item